We aim to positively surprise our customers and partners with innovative approaches
In Conversation
It's important not to forget the significant contributions made by the pharmaceutical industry during the pandemic. The promises and commitments made by industry players and governments…
We are steadily transforming from a relatively smaller player in generics and early-phase clinical studies to a broader and more relevant Contract Research Organization for our…
While generics continue to be a core focus, there has been a strategic shift towards emphasising innovation
Leveraging this resource [the Systeme National des Donnees de Sante (SNDS)], we conduct numerous real-world studies, positioning France among the leaders in real-world evidence generation within…
Over the next three years, our focus is set on three fundamental elements to drive growth and impact: portfolio transformation, capability building, and expanding the HCP…
Our collective journey to build a leading international dermatology company in India has just begun, and I am confident that with the dedication, passion, and unwavering…
[We must] avoid placing AI at the centre and then working backwards to find a problem. Instead, we should take a problem-centric approach, identifying real-world challenges…
Our aspirations are ambitious, aiming for a three-fold increase in size over the next 8-10 years
We have the experience, the footprint, the governance, and the ambition to leverage the opportunities ahead and forge a new path for pharmaceuticals in Gujarat
The funding landscape for science in Portugal is facing challenges that stem from a decrease in overall investment and shifting priorities. Despite the evident role of…
Our broad, global portfolio includes products that help treat the top 10 leading causes of death globally, as determined by the WHO
